Dapoxetine / Priligy 30 mg & 60 mg: U.S. Status and International Availability

Dapoxetine is the active ingredient in Priligy, a prescription medication authorized in a number of international markets for treatment of premature ejaculation. Priligy is available in 30 mg and 60 mg tablet strengths in markets where the product is authorized, but its regulatory status is not the same in every country. (ema.europa.eu)

For U.S. consumers researching dapoxetine, that distinction is particularly important: authorization of Priligy in European markets does not constitute FDA approval in the United States.

Dapoxetine vs. Priligy

Dapoxetine is the active substance.

Priligy is a brand name under which dapoxetine tablets have been authorized in multiple European/EEA markets.

European Medicines Agency documentation identifies Priligy as dapoxetine and documents 30 mg and 60 mg tablet strengths. Current Irish regulatory records likewise identify dapoxetine as the active substance in Priligy and maintain prescription-product records for the medicine. (ema.europa.eu)

As with other prescription medications, the brand name should not be used as a substitute for checking the exact product. Country, marketing authorization holder, manufacturer, strength and package should be verified from the current regulator-approved information for the market in which the medicine is being supplied.

What is Priligy used for?

Regulatory documentation for Priligy identifies its treatment context as premature ejaculation in adult men meeting the applicable diagnostic criteria. Dapoxetine is classified as a selective serotonin reuptake inhibitor, or SSRI, in the European product information. (ema.europa.eu)

It should not be described as though it were interchangeable with erectile-dysfunction medications such as sildenafil or tadalafil. Those medications have different active ingredients and therapeutic roles.

Someone researching dapoxetine should therefore distinguish between a treatment aimed at premature ejaculation and a medication intended to treat erectile dysfunction.

Priligy 30 mg vs. 60 mg

Regulator records document both Priligy 30 mg and Priligy 60 mg film-coated tablets. The two strengths contain the same active ingredient, dapoxetine, in different amounts. (ema.europa.eu)

The existence of a 60 mg tablet does not mean that 60 mg is automatically a better or more appropriate choice. Current European product information treats 30 mg as the initial strength and places conditions on use of the higher 60 mg strength. Dose selection is therefore a prescribing decision rather than a simple price or potency comparison. (assets.hpra.ie)

For commercial research, a comparison should focus on whether the quoted product is actually Priligy, which strength it contains, which market it is authorized for and whether the package information matches the regulator record.

Is dapoxetine FDA-approved in the United States?

As of October 6, 2026, current FDA approval databases do not identify dapoxetine or Priligy as an FDA-approved drug product in the United States.

Drugs@FDA and the FDA Orange Book are the relevant FDA approval sources checked for current U.S. drug-product status. Neither source identifies an approved dapoxetine/Priligy drug product. (fda.gov) (fda.gov)

Accordingly, Priligy should not be presented as an FDA-approved U.S. prescription product.

The existence of dapoxetine in an FDA substance, chemical or identifier database would not by itself establish approval of a dapoxetine drug product. U.S. approval status should be checked through the drug-approval databases themselves.

There is also no basis in the current FDA records checked for describing dapoxetine as having “FDA approval pending.”

International regulatory status

Dapoxetine has a different regulatory history outside the United States.

EMA records document a European regulatory procedure involving Priligy 30 mg and 60 mg tablets and national marketing authorizations based initially on a Swedish authorization granted in 2009. The European Commission issued its decision following the referral in January 2012. This history concerns European national and mutual-recognition authorization; it is not an FDA approval. (ema.europa.eu)

Current national records provide a more useful picture of present-day product status in a particular market. For example, Ireland's Health Products Regulatory Authority lists Priligy 30 mg as authorized and marketed, with dapoxetine as the active substance and prescription-only supply through pharmacies. Current HPRA product documentation also covers Priligy 60 mg. (hpra.ie)

The latest Irish patient information reviewed for this page identifies Phoenix Labs Unlimited Company as the marketing authorization holder and Menarini - Von Heyden GmbH as manufacturer, and lists Priligy under that name in numerous EEA markets. Those details relate to that current European product documentation and should not be assumed to identify every dapoxetine product offered internationally. (assets.hpra.ie)

Is Priligy prescription-only?

In regulated markets where the current product records specify prescription status, Priligy is a prescription medicine.

For example, the current Irish HPRA listing describes Priligy 30 mg as a product subject to prescription and supplied through pharmacies. (hpra.ie)

Requirements should still be checked for the specific country involved. An online reference to “OTC Priligy” or “dapoxetine without a prescription” should not be treated as evidence of the medicine's legal or regulatory status in a particular market.

Researching dapoxetine availability

Because U.S. and international status differ, availability research should begin with the country in which the medicine would actually be prescribed and dispensed.

Before relying on a product listing, verify:

Country or market: determine which regulator has jurisdiction.
Active ingredient: dapoxetine.
Brand: whether the product is actually Priligy or another dapoxetine product.
Strength: 30 mg or 60 mg where those strengths are authorized.
Marketing authorization holder: compare the package with current regulator records.
Manufacturer: verify the manufacturer named for that specific product rather than assuming all dapoxetine tablets come from one source.
Prescription requirement: check the current rules and product classification in that market.
Regulatory status: international authorization does not establish FDA approval.
Current availability: authorization does not guarantee that every pharmacy or wholesaler has a product in stock.

These checks are especially important when a website offers an imported medicine using only a brand name and strength without clearly identifying the country, authorization holder or package.

Price and access questions

A single universal “Priligy price” is not meaningful because dapoxetine is marketed under different regulatory and commercial conditions across countries.

Where Priligy is authorized, cost can be affected by the country, strength, package size, pharmacy, reimbursement arrangements and current commercial availability. A price quoted for a 30 mg product should not be compared directly with a different quantity or 60 mg presentation without confirming those details.

For a U.S. consumer, price research should not obscure the more fundamental issue: dapoxetine/Priligy is not currently listed as an FDA-approved drug product in the United States. International product listings therefore need to be evaluated in the context of the country where the medicine is actually authorized and dispensed.

Dapoxetine can be a useful secondary men's sexual-health research topic because Priligy is a real prescription product with documented international authorizations. Its role should remain specific, however: it is a premature-ejaculation medication with a regulatory position that differs substantially between the United States and markets where Priligy is authorized.